Core Viewpoint - The company, Borui Pharmaceutical, has received approval from the U.S. FDA to initiate Phase I clinical trials for BGM1812 injection aimed at treating overweight or obesity [1] Company Summary - BGM1812 injection is a newly designed long-acting Amylin analog with good molecular activity and pharmaceutical stability [1] - Amylin, a satiety hormone composed of 37 amino acids, is co-released with insulin from pancreatic beta cells into the bloodstream [1] Mechanism of Action - The drug activates brain pathways that promote satiety, suppresses appetite, delays gastric emptying, and inhibits glucagon secretion, thereby exhibiting multiple mechanisms for weight loss [1]